A whole lot lately about Notch3 and cancer..."more recent findings suggest that Notch3 signaling may play an important role in oncogenesis, tumor maintenance, and resistance to chemotherapy."
AVEO patent for its Notch3 antibody is a composition of matter patent. In other words, for the exact chemical make-up of the antibody (does not address use of the antibody). Very wide patent grant.
AVEO states they are looking for a partner for Av-353 for PAH...I bet part of the hold up is licensees want the rights to the patent for ALL applications, not just PAH.